후천성 희귀 혈액질환 치료제 시장 보고서 : 치료법, 질환별, 유통 채널, 지역별(2026-2034년)

The global acquired orphan blood diseases therapeutics market size reached USD 10.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 18.7 Billion by 2034, exhibiting a growth rate (CAGR) of 6.85% during 2026-2034. The increasing diagnosis rates of rare blood disorders, advancements in gene therapy and biologics, growing government support through orphan drug designations and regulatory incentives, the rising awareness of these conditions, and improvements in treatment efficacy are some of the major factors propelling the market growth.

ACQUIRED ORPHAN BLOOD DISEASES THERAPEUTICS MARKET ANALYSIS:

• Major Market Drivers: The rising prevalence and diagnosis of rare blood disorders, such as acquired hemophilia and paroxysmal nocturnal hemoglobinuria (PNH) represent the major driver of the market. As diagnostic tools improve, more cases are identified, increasing the demand for specialized treatments. Government support through orphan drug designations, financial grants, and extended market exclusivity further incentivizes pharmaceutical companies to invest in developing novel therapies for these rare diseases, making it financially viable for them to address small patient populations. Advancements in gene therapy, biologics, and precision medicine offer promising treatment options, thereby driving market growth.
• Key Market Trends: The growing focus on personalized medicine and targeted therapies represents the key trends in the market. Gene therapies and biologics are gaining traction due to their potential to address the underlying causes of rare blood disorders. Moreover, collaborations between biotech firms and pharmaceutical companies are increasing, accelerating drug development and commercialization. Another significant trend is the emphasis on patient advocacy and awareness, leading to earlier diagnoses and improved access to treatment.
• Geographical Trends: According to the acquired orphan blood diseases therapeutics market overview, North America accounts for the largest region in the market across the globe. Advanced healthcare infrastructure, increasing awareness and diagnosis of rare blood disorders, and significant investment in research and development (R&D) are driving the market growth across the region. Government incentives, such as orphan drug designations and grants, encourage pharmaceutical companies to develop treatments for these rare conditions. Strong advocacy and support networks also play a crucial role in improving patient access to therapies. In line with this, the rise of gene therapies, biologics, and personalized medicine technologies further enhances treatment options, thereby, in turn, enhancing the overall acquired orphan blood diseases therapeutics market value.
• Competitive Landscape: Some of the major market players in the acquired orphan blood diseases therapeutics industry include Alexion Pharmaceuticals Inc. (AstraZeneca plc), Amgen Inc., GSK plc, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co. Ltd., Rigel Pharmaceuticals Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited, among many others.
• Challenges and Opportunities: The market faces various challenges including high research and development (R&D) costs, limited patient populations, and complex regulatory pathways. However, the market also faces several opportunities, such as orphan drug status, which offers financial support and extended market exclusivity. Advances in gene therapy, biologics, and precision medicine create new therapeutic possibilities, while growing awareness and improved diagnostics enhance the early detection and treatment, thereby further expanding the market potential.

ACQUIRED ORPHAN BLOOD DISEASES THERAPEUTICS MARKET TRENDS:

Rising Prevalence of Rare Blood Disorders

The rise in cases of orphan blood diseases, such as hemophilia, paroxysmal nocturnal hemoglobinuria, and aplastic anemia, has created a growing need for targeted therapies. According to industry reports, India is home to the second-largest population of patients living with Haemophilia, with an estimated 1,36,000 individuals grappling with hemophilia A. However, only around 21,000 are registered at present. Nearly 80 percent of hemophilia cases are undiagnosed in India as several hospitals and medical institutions lack screening capabilities for blood clotting, affecting the diagnosis of new cases. As diagnostic techniques improve, more patients are being diagnosed, thus increasing the demand for specialized treatments, thus creating a positive acquired orphan blood diseases therapeutics market outlook.

Advances in Drug Development

Innovations in gene therapy, biologics, and precision medicine are transforming the treatment landscape for rare blood disorders. For instance, in April 2024, India launched its first home-grown gene therapy for cancer at IIT Bombay. Speaking on the occasion, the President of the country mentioned that the launch of India's first gene therapy is a breakthrough in the country's battle against cancer. As this line of treatment, named "CAR-T cell therapy", is accessible and affordable, it provides new hope for the whole of humankind. The President highlighted that CAR-T cell therapy is one of the most phenomenal advances in medical science. According to the acquired orphan blood diseases therapeutics market revenue, these breakthroughs offer more effective and personalized treatment options, which enhance patient outcomes and drive market growth.

Government Support and Orphan Drug Designations

Regulatory incentives such as orphan drug status, grants, and extended market exclusivity encourage pharmaceutical companies to develop drugs for rare blood diseases. For instance, in August 2024, Opaganib, a proprietary and investigational host-directed drug developed by Tel Aviv-based RedHill Biopharma, was given orphan drug designation by the FDA for the treatment of neuroblastoma, a type of cancer that is the most common malignancy among infants, with a median age of 17 months at the time of diagnosis. RedHill announced the FDA decision in a press release on Aug. 26, 2024. FDA has the authority to grant a drug or biological product "orphan" status if such a product prevents, diagnoses, or treats a rare disease or condition. Neuroblastoma is rare among children overall, accounting for up to 10% of all childhood cancers in the United States, where it affects 11 to 13 children per million under the age of 15-though that number rises to 65 per million under one year old, the equivalent of approximately 650 new cases every year. According to the acquired orphan blood diseases therapeutics market forecast, these incentives make it more financially viable to invest in research and development (R&D), thus contributing to the market's expansion.

ACQUIRED ORPHAN BLOOD DISEASES THERAPEUTICS MARKET SEGMENTATION:

Breakup by Therapy:

• Recombinant Factor
• Immunoglobulin Infusion Therapy
• Activated Prothrombin Complex Concentrate
• Thrombopoietin Receptor Agonists
• Others

Recombinant factor therapy is crucial for treating acquired hemophilia, providing a synthetic, non-human-derived clotting factor to control bleeding. Its efficacy in managing bleeding episodes with fewer risks of viral contamination makes it highly valuable in orphan blood disorders, driving its demand in the market, especially as it reduces dependency on plasma-derived products.

Immunoglobulin infusion therapy is widely used to manage autoimmune blood disorders, like acquired hemophilia and immune thrombocytopenia . It helps regulate immune system responses, controlling antibody-mediated destruction of platelets and red blood cells. Its ability to treat both acute and chronic conditions drives demand, making it an essential segment of the acquired orphan blood disease therapeutics market.

Activated prothrombin complex concentrate (aPCC) is vital for patients with hemophilia who develop inhibitors, offering an effective treatment to control bleeding by bypassing the need for the missing clotting factor. Its ability to manage life-threatening bleeds in hemophilia patients with inhibitors makes it a key therapeutic option, driving its demand in the orphan blood diseases market.

Thrombopoietin receptor agonists stimulate platelet production in patients with immune thrombocytopenia (ITP) and aplastic anemia. These drugs are critical for managing chronic low platelet counts, reducing the risk of bleeding complications. Their efficacy in increasing platelet levels in difficult-to-treat cases makes them a driving force in the market for treating rare acquired blood disorders.

Breakup by Disease Indication:

• Acquired Agranulocytosis
• Acquired Hemophilia
• Acquired Von Willebrand Syndrome
• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Myelodysplastic Syndrome
• Others

Acquired hemophilia holds the largest share of the industry

Acquired hemophilia accounts for the largest segment in the market due to its severe, life-threatening nature and the need for specialized treatment options. Patients with acquired hemophilia experience spontaneous bleeding episodes, requiring immediate intervention with targeted therapies like recombinant clotting factors, bypassing agents, or immunosuppressive treatments, which is further driving the acquired orphan blood diseases therapeutics demand. The rarity of the disorder, combined with growing awareness and improved diagnostics, drives the demand for effective therapies, making it the largest segment in this niche therapeutic market.

Breakup by Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Others

Hospital pharmacy represents the leading market segment

Hospital pharmacies account for the largest segment in the market due to their critical role in managing complex, severe cases of rare blood disorders. Hospitals provide specialized care and immediate access to advanced treatments, such as recombinant factors and immunoglobulin infusions, which are often required for managing acute and chronic conditions. The high level of patient monitoring and the need for tailored therapy in hospital settings drive the significant demand for these therapeutics, making hospital pharmacies the leading segment.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest acquired orphan blood diseases therapeutics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for acquired orphan blood diseases therapeutics.

In North America, the market is primarily driven by advanced healthcare infrastructure that supports the development and distribution of specialized treatments. Increased awareness and improved diagnostic capabilities lead to higher detection rates of rare disorders, thus driving the demand for targeted therapies. Government incentives, such as orphan drug designations and financial grants, encourage pharmaceutical companies to invest in drug development. Additionally, advancements in gene therapy and biologics offer new, effective treatment options, while strong patient advocacy and support networks enhance access to therapies, further propelling the acquired orphan blood diseases therapeutics market growth. For instance, in August 2023, Regeneron Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has approved Veopoz(TM) (pozelimab-bbfg) for the treatment of adult and pediatric patients 1 year of age and older with CHAPLE disease, also known as CD55-deficient protein-losing enteropathy. Veopoz is the first and only treatment indicated specifically for CHAPLE.

COMPETITIVE LANDSCAPE:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the acquired orphan blood diseases therapeutics industry include Alexion Pharmaceuticals Inc. (AstraZeneca plc), Amgen Inc., GSK plc, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co. Ltd., Rigel Pharmaceuticals Inc., Roche Holding AG, Sanofi, and Takeda Pharmaceutical Company Limited. ()
• The market is competitive, with key players such as Alexion Pharmaceuticals, Novartis, and Pfizer leading in drug development for rare blood disorders like paroxysmal nocturnal hemoglobinuria and aplastic anemia. These acquired orphan blood diseases therapeutics companies focus on innovative biologics, gene therapies, and immune-modulating treatments. Smaller biotech firms and startups are also entering the market, leveraging orphan drug designations and regulatory incentives. Competition is driven by advancements in treatment efficacy, pricing strategies, and efforts to secure extended market exclusivity. For instance, in December 2023, Novartis announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta(R) (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH]).

KEY QUESTIONS ANSWERED IN THIS REPORT

• How has the global acquired orphan blood diseases therapeutics market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global acquired orphan blood diseases therapeutics market?
• What is the impact of each driver, restraint, and opportunity on the global acquired orphan blood diseases therapeutics market?
• What are the key regional markets?
• Which countries represent the most attractive acquired orphan blood diseases therapeutics market?
• What is the breakup of the market based on the therapy?
• Which is the most attractive therapy in the acquired orphan blood diseases therapeutics market?
• What is the breakup of the market based on the disease indication?
• Which is the most attractive disease indication in the acquired orphan blood diseases therapeutics market?
• What is the breakup of the market based on the distribution channel?
• Which is the most attractive distribution channel in the acquired orphan blood diseases therapeutics market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global acquired orphan blood diseases therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Acquired Orphan Blood Diseases Therapeutics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Therapy

• 6.1 Recombinant Factor
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Immunoglobulin Infusion Therapy
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Activated Prothrombin Complex Concentrate
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Thrombopoietin Receptor Agonists
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Disease Indication

• 7.1 Acquired Agranulocytosis
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Acquired Hemophilia
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Acquired Von Willebrand Syndrome
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Myelodysplastic Syndrome
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacy
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacy
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Alexion Pharmaceuticals Inc. (AstraZeneca plc)
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Amgen Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 GSK plc
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Novartis AG
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Novo Nordisk A/S
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Otsuka Pharmaceutical Co. Ltd.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Rigel Pharmaceuticals Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Roche Holding AG
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
  • 14.3.9 Sanofi
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Takeda Pharmaceutical Company Limited
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis